Printer Friendly

CYTRX ANNOUNCES PATENT APPLICATION

 CYTRX ANNOUNCES PATENT APPLICATION
 NORCROSS, Ga., May 21 /PRNewswire/ -- CytRx Corporation


(NASDAQ: CYTR) announced today that it has filed a comprehensive patent application for a broad group of synthetic copolymer gels to be used in breast implants.
 Jack J. Luchese, president and chief executive officer, said: "We believe we may have found the solution to a very difficult problem with a new material which may overcome the problems associated with current silicone breast implants. The group of synthetic copolymer gels we intend to develop for use in breast implants appear to us in preliminary studies to be inherently safe and afford the opportunity to vary viscosity levels for the individual needs of both the patients and the surgeons performing the various procedures. We intend to begin safety studies in the near future leading to clinical trials in 1993. At the present time we have not determined whether we will keep this technology or make it available for licensing to a medical device manufacturer."
 CytRx Corporation is a biopharmaceutical company engaged in the research and development of therapeutics incorporating copolymers. The company is developing human pharmaceutical products intended for use in the treatment of vascular, immune system and infectious diseases as well as burns. The company is also developing feed additives intended for growth enhancement in food animals, adjuvants for use in both human and veterinary vaccines and is currently marketing Hunter's TiterMax(TM), an immunoadjuvant for use by the basic research community.
 -0- 5/21/92
 /CONTACT: Judy Jones of CytRx, 404-368-9500/
 (CYTR) CO: CytRx Corporation ST: Georgia IN: MTC SU:


EA-BR -- AT006 -- 2677 05/21/92 09:28 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 21, 1992
Words:270
Previous Article:NORFOLK SOUTHERN ANNOUNCES MODERNIZATION STUDY OF LAMBERTS POINT PLANT
Next Article:MAIN ST. & MAIN INC. ANNOUNCES FIRST QUARTER PROFIT
Topics:


Related Articles
CYTRX CORPORATION LICENSES OPHTHALMIC PATENT FROM BRUJO CORPORATION
CYTRX CORPORATION ANNOUNCES 1995 THREE MONTHS RESULTS
CYTRX CORPORATION ANNOUNCES 1996 FIRST QUARTER RESULTS
CytRx Announces Issuance of TRANZFECT Patent.
CytRx Receives $2 Million Initial Fee Under TranzFect License to Merck.
CytRx Licenses TranzFect Poloxamer Technology to Vical.
CytRx Corporation, Advanced BioScience Laboratories and University of Massachusetts Announce Filing of Investigational New Drug Application for...
CytRx Announces Plans for Filing of Investigational New Drug Application for HIV Vaccine and Strategic Alliance With Advanced BioScience Laboratories.
CytRx Acquires Broad Product License for Breakthrough DNA-Based HIV Vaccine; - Secures Company's Worldwide Leadership Role in HIV Vaccine...
CytRx Meets All Compliance Requirements to Continue Nasdaq Listing.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters